Skip to main content
TTrialFinderData
TrialFinderData is for informational purposes only and does not provide medical advice. Always talk to your doctor.

Stomach Cancer Clinical Trials

Reviewed by TrialFinderData Editorial Team · Updated

103 recruiting trials for Stomach Cancer. Eligibility criteria explained in plain English.

TrialFinderData lists 103 Stomach Cancer clinical trials drawn from ClinicalTrials.gov, all of which are currently recruiting participants.

Across the trials that carry a phase, Phase 2 is the largest group at 26% (16 studies); the largest phase groups are Phase 2: 16, Phase 1 / Phase 2: 14, Phase 1: 12, Phase 3: 11.

Research is led by Fudan University (5), Cancer Institute and Hospital, Chinese Academy of Medical Sciences (2), AstraZeneca (2), among the most active sponsors registered for these trials.

The most frequently studied intervention is Oxaliplatin (drug, 7 trials), followed by Pembrolizumab, Paclitaxel.

Important: This information is not medical advice. Talk to your doctor about whether a clinical trial is right for you.
103
Total Trials
103
Recruiting Now
11
Phase 3 Trials
10
Sponsors

Track Stomach Cancer trials

Subscribe for TrialFinderData updates by email. No spam, unsubscribe anytime.

Recruiting Trials

Clinical trial data sourced from the ClinicalTrials.gov registry, maintained by the National Library of Medicine. Always consult your doctor before considering any clinical trial.

RECRUITINGPhase 1NCT06673329

Brodalumab in the Treatment of Immune-Related Adverse Events

The purpose of this study is to test the safety and effectiveness of using brodalumab in patients who develop side effects from cancer immune therapy. Immune-related side effects...

Sponsor: Brian Henick, MDEnrolling: 111 location
RECRUITINGNCT05366881

cfDNA Assay Prospective Observational Validation for Early Cancer Detection and Minimal Residual Disease

This is an observational case-control study to train and validate a genome-wide methylome enrichment platform to detect multiple cancer types and to differentiate amongst cancer...

Sponsor: Adela, IncEnrolling: 700017 locations
RECRUITINGPhase 2NCT07176312

Zanidatamab in Combination With Pembrolizumab and Chemotherapy in HER2 and PD-L1 Positive Metastatic Gastroesophageal...

The ZANGEA trial is a open-label, single arm, multicenter phase II trial assessing the efficacy of zanidatamab in combination with pembrolizumab and chemotherapy in patients with...

Sponsor: Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus NordwestEnrolling: 8020 locations
RECRUITINGNCT06417892

Fruquintinib and Albumin-paclitaxel Combined With or Without PD-1 Antibody in 2nd-line Treatment of G/GEJ Adenocarcinoma

To explore the efficacy and safety of fruquintinib and albumin-paclitaxel combined with or without PD-1 antibody in the second-line treatment of advanced gastric/gastroesophageal...

Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical SciencesEnrolling: 601 location
RECRUITINGPhase 1 / Phase 2NCT06921837

A First-in-Human Study Using BDC-4182 as a Single Agent in Advanced Gastric and Gastroesophageal Cancer

A first-in-human study using BDC-4182 as a single agent in gastric and gastroesophageal cancers

Sponsor: Bolt Biotherapeutics, Inc.Enrolling: 12216 locations
RECRUITINGPhase 2NCT07282912

Trial Comparing Standard of Care Therapy With and Without Sequential Cytoreductive Intervention for Patients With...

This is a randomized, open label, single-center, phase 2, randomized controlled trial of sequential cytoreductive intervention versus standard of care therapy for patients with...

Sponsor: Yale UniversityEnrolling: 541 location
RECRUITINGNCT05344339

Billroth-II Modified Versus Roux-en-Y After Distal Gastrectomy for Gastric Cancer

There are Billroth-I, Billroth-II, Billroth-II with Braun, and Roux-en-Y reconstruction after distal gastrectomy. Hypothesis: Billroth-II modified method is non-inferior to...

Sponsor: University Medical Center Ho Chi Minh City (UMC)Enrolling: 3201 location
RECRUITINGPhase 3NCT05226169

Efficacy and Safety oF FErric CarboxymalTose in Patients With Advanced Gastric Cancer(EFFECT-AGC)

The main objective of this study is to evaluate the efficacy and safety of IV FCM(ferric carboxymaltose) in patients with AGC receiving palliative chemotherapy. This study will...

Sponsor: Asan Medical CenterEnrolling: 3301 location
RECRUITINGPhase 1 / Phase 2NCT06921928

Study for AZD4360 in Participants With Advanced Solid Tumours

The purpose of this study is to evaluate the safety, tolerability, PK, immunogenicity, pharmacodynamics, and preliminary efficacy of AZD4360 in adult participants with locally...

Sponsor: AstraZenecaEnrolling: 11718 locations
RECRUITINGPhase 1 / Phase 2NCT07334431

Fruquintinib Combined With Trastuzumab and XELOX as First-line Treatment in Patients With HER2-positive Advanced...

This study was designed to evaluate the safety and efficacy of fruquintinib plus trastuzumab, and XELOX as first-line treatment for HER2-positive advanced gastric or...

Sponsor: Henan Cancer HospitalEnrolling: 451 location
RECRUITINGPhase 1 / Phase 2NCT07523529

Biomarker-Guided Dual-Target CAR-T Cells for Advanced Solid Tumors

This is a multicenter, open-label, Phase 1/2 master protocol evaluating autologous dual-target CAR-T cell therapy in adults with advanced solid cancers. After central biomarker...

Sponsor: Beijing BiotechEnrolling: 721 location
RECRUITINGEarly Phase 1NCT07034742

Exploratory Study on the Application of Molecular Residual Disease (MRD) in Postoperative Treatment of Gastric Cancer

Gastric cancer is one of the most prevalent and lethal malignancies in China. The majority of patients are diagnosed at the locally advanced stage. Despite standard treatment...

Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical SciencesEnrolling: 1361 location
RECRUITINGNCT06490159

Predicting Peripheral Neuropathy of Paclitaxel for Gastric Cancer

Although advances in chemotherapy have improved the prognosis of gastric cancer patients, many patients still suffer from adverse events. Therefore, it is necessary to establish...

Sponsor: City of Hope Medical CenterEnrolling: 1501 location
RECRUITINGNCT04547725

Complete Cytoreduction Followed by IP and Systemic Chemotherapies for Gastric Cancer With Peritoneal Carcinomatosis

Background: Approximately 15% of gastric adenocarcinoma patients presents with peritoneal carcinomatosis (PC) at the first encounter and is regarded as an unresectable and...

Sponsor: National Taiwan University HospitalEnrolling: 481 location
RECRUITINGPhase 4NCT05183126

Pharmacokinetic Study of Skeletal Muscle Area-based Paclitaxel Infusion in Patients With Cancer

The primary objective of this pharmacokinetics study is to compare the maximum concentration level of paclitaxel in patients with low/sarcopenic skeletal muscle area (SMA), at the...

Sponsor: University of Michigan Rogel Cancer CenterEnrolling: 221 location
RECRUITINGPhase 3NCT07315750

A Study of Disitamab Vedotin Combined With Trastuzumab and Tislelizumab Versus Chemotherapy Combined With Trastuzumab...

The purpose of this study is to evaluate the efficacy and safety of Disitamab Vedotin combined with Trastuzumab and Tislelizumab Versus Chemotherapy Combined with Trastuzumab with...

Sponsor: RemeGen Co., Ltd.Enrolling: 5551 location
RECRUITINGPhase 2NCT06422403

A Value-Driven Study on Reducing Immune Checkpoint Inhibitor Dosing Frequency in Advanced Cancers

This study is a prospective, open label, multi-centre phase 2 trial which assesses the efficacy and safety of standard dosing compared to extended dosing interval of nivolumab,...

Sponsor: National University Hospital, SingaporeEnrolling: 3601 location
RECRUITINGPhase 1NCT06427941

A Phase 1 Study of BGB-B2033, Alone or in Combination With Tislelizumab With or Without Bevacizumab, in Participants...

This is a first-in-human (FIH) clinical study designed to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and anti-tumor activity of BGB-B2033...

Sponsor: BeOne MedicinesEnrolling: 39220 locations
RECRUITINGPhase 2NCT06405113

FMT+SOX+Sintilimab As First-line Treatment for Advanced Gastric Cancer

the investigators plan to initiate a prospective, multicenter, randomized, double-blind, placebo-controlled phase II study, recruiting 198 patients with advanced...

Sponsor: Changzhou No.2 People's HospitalEnrolling: 1981 location
RECRUITINGNCT06726642

CfDNA in Hereditary And High-risk Malignancies 2

The goal of this study is to understand the performance of an experimental blood test that aims to detect early tumors in patients with hereditary cancer syndromes. If this new...

Sponsor: University Health Network, TorontoEnrolling: 10008 locations
RECRUITINGNCT06869694

Energy CT in Imaging and Diagnosis of Gastric Cancer

Accurate preoperative prediction of risk stratification, treatment response, and survival prognosis in gastric cancer is important for improving clinical treatment decisions,...

Sponsor: The First Affiliated Hospital of Zhengzhou UniversityEnrolling: 3001 location
RECRUITINGPhase 2NCT07537361

Safety and Efficacy of Leucine-Restricted Diet Combined With Neoadjuvant Chemotherapy and Immunotherapy in Gastric...

Consistent with previous literature, the investigators postulate that a leucine-restricted diet is safe and well-tolerated in gastric cancer patients receiving neoadjuvant...

Sponsor: Qilu Hospital of Shandong UniversityEnrolling: 1081 location
RECRUITINGPhase 1NCT05802056

Aldesleukin With Nivolumab and Standard Chemotherapy for Treatment of Gastric Cancer With Peritoneal Metastasis

This phase Ib trial test effects of aldesleukin in combination with nivolumab and standard chemotherapy in treating patients with gastric cancer that has spread to the tissue...

Sponsor: Mayo ClinicEnrolling: 151 location
RECRUITINGNCT02838836

Tumor Cell and DNA Detection in the Blood, Urine and Bone Marrow of Patients With Solid Cancers

Patients with resectable solid primary cancers and even limited number of metastases are potentially curable. However, most patients develop recurrences despite surgery....

Sponsor: University of Missouri-ColumbiaEnrolling: 6201 location
RECRUITINGPhase 2NCT06555471

A Single-arm, Phase II Exploratory Study of Sintilimab in Combination With Chemoradiotherapy in Elderly Patients With...

This trial is a prospective, single-arm, single-centre, phase II clinical study to explore the efficacy and safety of sintilimab in combination with chemoradiation in subjects...

Sponsor: The First Affiliated Hospital with Nanjing Medical UniversityEnrolling: 401 location
RECRUITINGNCT04809025

Comparation of Endoscopic Biopsy and Postoperative Specimen for the Molecular Diagnosis of Gastric Cancer

This study aims to test the hypothesis that the diagnosis for histological type, histological grade, LAUREN type, HER-2 expression, MSI/dMMR status, and EBV status in gastric...

Sponsor: Fudan UniversityEnrolling: 5101 location
RECRUITINGNCT06961526

Esophageal Varices Prophylaxis in Hepatocellular Carcinoma Treated With Atezolizumab and Bevacizumab

The goal of this prospective cohort study is to evaluate the progression of esophagogastric varices in patients treated with atezolizumab-bevacizumab. Assess the efficacy of...

Sponsor: Tanta UniversityEnrolling: 1101 location
RECRUITINGPhase 2NCT06792162

PD-1 Antibody Carilizumab Combined with Apatinib for Unresectable Stage III and IV DMMR Gastric Cancer

Evaluate the safety and efficacy of PD-1 antibody Carilizumab combined with apatinib for the conversion therapy of unresectable stage III and IV dMMR gastric cancer.

Sponsor: Peking University Third HospitalEnrolling: 201 location
RECRUITINGNCT07069842

The Construction of a Predictive Model for Gastric Cancer Immunotherapy Response Based on Tumor-Infiltrating...

Gastric cancer is one of the cancers with a high mortality rate globally, and its treatment outcomes urgently need to be improved. The emergence of immunotherapy has broken...

Sponsor: Changzhi People's Hospital Affiliated to Changzhi Medical CollegeEnrolling: 1701 location
RECRUITINGPhase 3NCT05264896

Perioperative FLOT vs Adjuvant XELOX for CA Stomach

This is a single centre randomised controlled trial, comparing perioperative FLOT versus adjuvant XELOX for locally advanced gastric and esophagogastric junction cancers. Patients...

Sponsor: Chinese University of Hong KongEnrolling: 1101 location
RECRUITINGPhase 1 / Phase 2NCT05636618

Targeted Alpha-Particle Therapy for Advanced Somatostatin Receptor Type 2 (SSTR2) Positive Tumors

This study is Phase I/IIa First-in-Human Study of \[212Pb\]VMT-α-NET Targeted Alpha-Particle Therapy for Advanced SSTR2 Positive Tumors

Sponsor: Perspective TherapeuticsEnrolling: 30019 locations
RECRUITINGNCT05347524

Detection of Peritoneal Metastasis of Gastric Cancer by Liquid Biopsy in Peripheral Blood: A Prospective Study

This study is a prospective, multi-omics, observational study aimed at detecting peritoneal metastasis of gastric cancer by combined assays for methylation of cell-free DNA...

Sponsor: Shanghai Zhongshan HospitalEnrolling: 3841 location
RECRUITINGNCT07660627

Determining Minimal Residual Disease Using ctDNA Deep Sequencing

Preoperative neoadjuvant chemotherapy is the standard treatment for locally advanced gastrointestinal tumours. However, not all patients respond to preoperative treatment. Early...

Sponsor: Masaryk Memorial Cancer InstituteEnrolling: 341 location
RECRUITINGPhase 1NCT04329494

PIPAC for the Treatment of Peritoneal Carcinomatosis in Patients With Ovarian, Uterine, Appendiceal, Colorectal, or...

This phase I trial studies the side effects of pressurized intraperitoneal aerosol chemotherapy (PIPAC) in treating patients with ovarian, uterine, appendiceal, stomach (gastric),...

Sponsor: City of Hope Medical CenterEnrolling: 493 locations
RECRUITINGPhase 2 / Phase 3NCT07018661

[18F]F-FAPI PET/CT and Laparoscopy in Staging Advanced Gastric Cancer

The goal of this clinical trial is to learn if a new type of scan, FAPI-PET/CT, can help find metastases of gastric cancer. We want to know how well this scan works for this...

Sponsor: Leiden University Medical CenterEnrolling: 25010 locations
RECRUITINGPhase 1 / Phase 2NCT00722228

Autologous and Allogeneic Whole Cell Cancer Vaccine for Metastatic Tumors

This study is based on the finding that tumor cells that are grown in the laboratory can be modified in such a way that, when injected to the patient, they will stimulate his/her...

Sponsor: Hadassah Medical OrganizationEnrolling: 501 location
RECRUITINGPhase 1 / Phase 2NCT05269381

Personalized Neoantigen Peptide-Based Vaccine in Combination With Pembrolizumab for Treatment of Advanced Solid Tumors

This phase I/II trial tests the safety and tolerability of an experimental personalized vaccine when given by itself and with pembrolizumab in treating patients with solid tumor...

Sponsor: Mayo ClinicEnrolling: 1321 location
RECRUITINGNCT06602037

ImmunoPET Imaging of Pancreatic Cancer

Pancreatic cancer remains one of the most aggressive cancer types. Target-specific targeted therapy is an attractive therapeutic alternative for the treatment of patients with a...

Sponsor: RenJi HospitalEnrolling: 901 location
RECRUITINGNCT05722275

Prediction of Peritoneal Metastasis for Gastric Cancer Based on Radiomics

Peritoneal metastasis of gastric cancer is difficult to be detected in time, thus delaying treatment. Based on the conventional CT images of gastric cancer, this study plans to...

Sponsor: Chinese Academy of SciencesEnrolling: 40013 locations
RECRUITINGPhase 1 / Phase 2NCT03190941

Administering Peripheral Blood Lymphocytes Transduced With a Murine T-Cell Receptor Recognizing the G12V Variant of...

Background: A new cancer therapy involves taking white blood cells from a person, growing them in the lab, genetically modifying them, then giving them back to the person. This...

Sponsor: National Cancer Institute (NCI)Enrolling: 1101 location
RECRUITINGPhase 2 / Phase 3NCT06721520

Effectiveness of Methods for Pyloric Drainage in esophagecTomY: Botox vs. Pyloromyotomy

The goal of this pragmatic, registry-based, randomized clinical trial is to find out if using botulinum toxin (Botox) to help drain the stomach during an esophagectomy works as...

Sponsor: The Cleveland ClinicEnrolling: 1701 location
RECRUITINGPhase 1NCT06999187

A Study of DR-0202 in Patients With Locally Advanced or Metastatic, Relapsed or Refractory Carcinomas

A phase 1a/1b, multicenter, open-label, dose escalation/expansion, multiple-dose study to evaluate the safety and activity of DR-0202 in patients with locally advanced or...

Sponsor: Dren BioEnrolling: 9610 locations
RECRUITINGPhase 1 / Phase 2NCT06298916

64Cu-LNTH-1363S in Patients With Sarcoma or Gastrointestinal Tract Cancer

This is a multicenter, open-label, prospective Phase 1/2a study to assess safety and tolerability, establish dosimetry and to identify an optimal imaging dose (radioactivity) and...

Sponsor: Lantheus Medical ImagingEnrolling: 265 locations
RECRUITINGPhase 1NCT07646106

THE-0504 in Patients With Solid Tumors

Single-centre, open-label, dose escalation phase I clinical trial, designed to evaluate mainly the safety and tolerability of the antitumor drug THE-0504 in patients with...

Sponsor: Thena Biotech S.r.l.Enrolling: 301 location
RECRUITINGPhase 2NCT06333314

Dostarlimab for Locally Advanced or Metastatic Cancer (Non-colorectal/Non-endometrial) With Tumor dMMR/MSI

The goal of this open-label randomized, multicenter, comparative phase II trial is to evaluate the efficacy of the immunotherapy, dostarlimab, as first-line treatment for...

Sponsor: UNICANCEREnrolling: 12020 locations
RECRUITINGNCT07067983

Clinical Evaluation of GRAPE Model for Gastric Cancer Screening

A Prospective Study Evaluating the Performance of the GRAPE Model in Gastric Cancer Screening and Its Detection Rates Across Different Disease Stages

Sponsor: Zhejiang Cancer HospitalEnrolling: 10000001 location
RECRUITINGNCT04295473

Reduced Port Laparoscopic Gastrectomy for Gastric Cancer

Reduced port laparoscopic gastrectomy has been adopted in clinical. The safety and outcome of reduced port laparoscopic gastrectomy has not been systematically evaluated. The...

Sponsor: Nanchong Central HospitalEnrolling: 1601 location
RECRUITINGEarly Phase 1NCT06828588

Pilot Study of [68Ga]Ga-ABY-025 Imaging in Patients Undergoing Treatment With HER2-targeted Therapy

The purpose of this study is to determine if the radiotracer, \[68Ga\]Ga-ABY-025, used for PET imaging can help us better identify and visualize lesions or tumors, in patients who...

Sponsor: Vanderbilt-Ingram Cancer CenterEnrolling: 301 location
RECRUITINGPhase 2NCT04519151

Pembrolizumab and Lenvatinib for Platinum- Sensitive Recurrent Ovarian Cancer

This is a study of pembrolizumab (MK-3475, KEYTRUDA®) in combination with lenvatinib (E7080) for the treatment of platinum sensitive recurrent ovarian cancer. Participants will...

Sponsor: Sheba Medical CenterEnrolling: 241 location
RECRUITINGNCT03787056

Predictive Value of Progastrin Titer at Diagnosis and of Progastrin Kinetics During Treatment in Cancer Patients

Progastrin is a pro-hormone that, in physiological conditions, is maturated in gastrin in G cells of the stomach. The role of the gastrin is to stimulate the secretion of gastric...

Sponsor: Hospices Civils de LyonEnrolling: 41017 locations

Showing 50 of 103 trials.Search all Stomach Cancer trials

Frequently Asked Questions

There are currently 103 clinical trials for Stomach Cancer, with 103 actively recruiting participants. These include trials across all phases from early-stage Phase 1 to late-stage Phase 3.

To join a clinical trial for Stomach Cancer, review the eligibility criteria on the trial detail pages, then talk to your doctor about whether a trial is right for you. Your doctor can help you evaluate the potential benefits and risks.

Phase 3 trials are large-scale studies that test whether a treatment is effective and monitor side effects. There are 11 Phase 3 trials for Stomach Cancer, representing treatments closest to potential FDA approval.

Clinical trials follow strict safety protocols overseen by Institutional Review Boards (IRBs) and the FDA. Participants are monitored closely and can withdraw at any time. Always discuss risks and benefits with your healthcare provider before enrolling.

Sources: ClinicalTrials.gov, FDA
Last updated:

Trial data sourced from the ClinicalTrials.gov API. This site does not provide medical advice, always talk to your doctor about clinical trial participation.